{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:49:54Z","timestamp":1793508594615,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.trecan.2025.11.008","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:48:17Z","timestamp":1764679697000},"page":"105-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chemotherapy-free cancer treatment \u2013 not for everyone yet"],"prefix":"10.1016","volume":"12","author":[{"given":"Caroline","family":"Donz\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6786-4968","authenticated-orcid":false,"given":"Nicolas","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.11.008_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.11.008_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0020","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd2084","article-title":"Case histories, magic bullets and the state of drug discovery","volume":"5","author":"Drews","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.11.008_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0030","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0035","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0040","first-page":"87","article-title":"Future perspectives on engineered T cells for cancer","volume":"106","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0045","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.trecan.2020.01.011","article-title":"Nanotherapeutics for immuno-oncology: a crossroad for new paradigms","volume":"6","author":"Song","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0055","first-page":"3","article-title":"Antibody drug conjugate: the 'biological missile' for targeted cancer therapy","volume":"79","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2025.11.008_bb0060","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0065","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0075","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jama.2024.23560","article-title":"Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: the CamRelief Randomized Clinical Trial","volume":"333","author":"Chen","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2025.11.008_bb0090","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic response of Phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0095","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.11.008_bb0100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0105","first-page":"2","article-title":"Gastrointestinal stromal tumours","volume":"72","author":"Blay","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.trecan.2025.11.008_bb0110","first-page":"10","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"216","author":"Sen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0115","first-page":"415","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"3871","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.11.008_bb0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.trecan.2025.01.005","article-title":"Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer","volume":"11","author":"Waliany","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0125","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1158\/2159-8290.CD-24-1476","article-title":"Precision oncology: 2024 in review","volume":"14","author":"Repetto","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.11.008_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0135","first-page":"973","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"3861","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0140","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.11.008_bb0145","article-title":"Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy","volume":"142","author":"Gbadamosi","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2025.11.008_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","article-title":"Hyperprogression and immunotherapy: fact, fiction, or alternative fact?","volume":"6","author":"Adashek","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0155","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1093\/oncolo\/oyad043","article-title":"Low risk of hyperprogression with first-line chemoimmunotherapy for advanced non-small cell lung cancer: pooled analysis of 7 clinical trials","volume":"28","author":"Li","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.trecan.2025.11.008_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1478377","article-title":"Comparison of the efficacy and safety of perioperative immunochemotherapeutic strategies for locally advanced esophageal cancer: a systematic review and network meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.11.008_bb0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.11.008_bb0175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","article-title":"Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions","volume":"22","author":"Wang","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0180","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0185","first-page":"15","article-title":"Recent progress in the treatment of cancer in children","volume":"713","author":"Butler","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.trecan.2025.11.008_bb0190","first-page":"175","article-title":"Clinical care for people who survive childhood cancer: a review","volume":"3301","author":"Bhatia","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2025.11.008_bb0195","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0140-6736(14)62395-3","article-title":"Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial","volume":"386","author":"Pritchard-Jones","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.11.008_bb0200","first-page":"617","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"191","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0205","first-page":"108","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"3891","author":"Bouffet","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group AAML1331 Trial","volume":"8","author":"Kutny","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0215","first-page":"15308","article-title":"Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions","volume":"2201","author":"Desai","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31397","article-title":"Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children","volume":"72","author":"Pereira","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0225","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial","volume":"28","author":"Le Deley","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0230","article-title":"Bayesian approaches to include real-world data in clinical studies","volume":"381","author":"M\u00fcller","year":"2023","journal-title":"Philos. Trans. A Math. Phys. Eng. Sci."},{"key":"10.1016\/j.trecan.2025.11.008_bb0235","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0240","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.22.02875","article-title":"Eflornithine as post-immunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons","volume":"42","author":"Oesterheld","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0245","first-page":"93","article-title":"Holistic pediatric oncology: towards a second Copernican revolution","volume":"96","author":"Andr\u00e9","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0250","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody\u2013drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0255","first-page":"783","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"3671","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0260","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.11.008_bb0270","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0275","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11523-025-01140-w","article-title":"Navigating the landscape of resistance mechanisms in antibody\u2013drug conjugates for cancer treatment","volume":"20","author":"Lalli","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0280","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0285","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1038\/s41591-024-03088-2","article-title":"Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial","volume":"30","author":"Mo","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0290","first-page":"843","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"3851","author":"Simkens","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.11.008_bb0295","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.11.008_bb0300","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.trecan.2020.05.007","article-title":"Metronomic maintenance for high-risk pediatric malignancies: one size will not fit all","volume":"6","author":"Andr\u00e9","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0305","first-page":"856","article-title":"Maintenance chemotherapy in patients with high-risk rhabdomyosarcoma: long-term survival analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial","volume":"431","author":"Bisogno","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0310","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annonc.2024.12.005","article-title":"ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0315","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States","volume":"36","author":"Gordon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217437","article-title":"Metronomic chemotherapy and drug repurposing: two sides of an oncology coin to reduce host and financial toxicity","volume":"613","author":"Andr\u00e9","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2025.11.008_bb0325","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","article-title":"Sodium thiosulfate for protection from cisplatin-induced hearing loss","volume":"378","author":"Brock","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0330","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"J. Clin. Oncol. Precis. Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0335","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.04.019","article-title":"Mass cytometry: single cells, many features","volume":"165","author":"Spitzer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.11.008_bb0340","first-page":"208","article-title":"Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity","volume":"521","author":"Kinker","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2025.11.008_bb0345","first-page":"178","article-title":"Tumour evolution and microenvironment interactions in 2D and 3D space","volume":"6341","author":"Mo","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.11.008_bb0350","first-page":"5","article-title":"Convergence of evolving artificial intelligence and machine learning techniques in precision oncology","volume":"87","author":"Fountzilas","year":"2025","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0355","first-page":"1","article-title":"pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens","volume":"81","author":"Hundal","year":"2016","journal-title":"Genome Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0360","first-page":"20","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"192","author":"Chen","year":"2018","journal-title":"Genome Biol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0365","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.trecan.2025.03.005","article-title":"The future of tumor organoids in precision therapy","volume":"11","author":"Kim","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0370","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2020.11.001","article-title":"Next-generation liquid biopsies: embracing data science in oncology","volume":"7","author":"Im","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.11.008_bb0375","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0380","first-page":"417","article-title":"Hallmarks of artificial intelligence contributions to precision oncology","volume":"6","author":"Chang","year":"2025","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2025.11.008_bb0385","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-15-0124","article-title":"Failures in Phase III: causes and consequences","volume":"21","author":"Seruga","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.11.008_bb0390","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0395","first-page":"9","article-title":"The next generation of evidence-based medicine","volume":"294","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.11.008_bb0400","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-cancerbio-061421-012927","article-title":"Basket trials: past, present, and future","volume":"8","author":"Murciano-Goroff","year":"2024","journal-title":"Ann. Rev Cancer Biol."},{"key":"10.1016\/j.trecan.2025.11.008_bb0405","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12874-024-02272-9","article-title":"Adaptive designs in clinical trials: a systematic review-part I","volume":"24","author":"Ben-Eltriki","year":"2024","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325002821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325002821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:15:10Z","timestamp":1773936910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325002821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2405803325002821"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.11.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy-free cancer treatment \u2013 not for everyone yet","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}